Inactive Instrument

WuXi Biologics (Cayman) Inc. Share Price Hong Kong S.E.

Equities

2269

KYG970081090

Biotechnology & Medical Research

Financials

Sales 2024 * 18.12B 2.49B 19.47B 197B Sales 2025 * 20.99B 2.89B 22.55B 229B Capitalization 45.12B 6.21B 48.47B 491B
Net income 2024 * 3.85B 529M 4.13B 41.88B Net income 2025 * 4.61B 634M 4.95B 50.17B EV / Sales 2024 * 2.09 x
Net cash position 2024 * 7.25B 997M 7.79B 78.94B Net cash position 2025 * 8.19B 1.13B 8.8B 89.17B EV / Sales 2025 * 1.76 x
P/E ratio 2024 *
12.2 x
P/E ratio 2025 *
10.1 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14 MT
Wuxi Biologics Terms US Plant's Expansion Halt as Normal Business Adjustment MT
WuXi Biologics Surges to 19-Month High Wednesday on Hopes of Avoiding US Ban MT
US lawmakers ask FBI for briefing on GenScript Biotech's links to China RE
US lawmakers ask FBI for briefing on GenScript Biotech's links to China RE
China stocks rise as industrial profits grow; energy, semiconductor shares lead gains RE
Wuxi Biologics (Cayman) Maintains it is Not a Security Threat After House Bill Changes; Stocks Drop 3% MT
US House committee advances bill to restrict BGI, WuXi AppTec RE
US House committee to vote on bill to restrict BGI, WuXi AppTec RE
US Congress Drafts Bill Asking Drug Firms to Unlink from Chinese Biotech Firms MT
WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling DJ
U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties RE
Pacific Assets Trust cautiously optimistic after outpacing benchmark AN
Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer CI
WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump MT
More news
Managers TitleAgeSince
Chief Executive Officer 52 31/05/11
Director of Finance/CFO 54 22/08/21
Chief Tech/Sci/R&D Officer 57 -
Members of the board TitleAgeSince
Director/Board Member 73 05/05/23
Director/Board Member 75 16/05/17
Chairman 56 30/04/10
More insiders
WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.
Related indices
More about the company